Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1745-6215
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Combination of first-line chemotherapy with Kanglaite injections versus first-line chemotherapy alone for advanced non-small-cell lung cancer: study protocol for an investigator-initiated, multicenter, open-label, randomized controlled trial ; volume:22 ; number:1 ; day:17 ; month:3 ; year:2021 ; pages:1-9 ; date:12.2021
Trials ; 22, Heft 1 (17.3.2021), 1-9, 12.2021

Urheber
Gao, Ruike
Zhang, Ying
Hou, Wei
Li, Jie
Zhu, Guanghui
Zhang, Xiaoxiao
Xu, Bowen
Wu, Zhe
Wang, Heping
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s13063-021-05169-w
URN
urn:nbn:de:101:1-2021050420042356818376
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:53 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Gao, Ruike
  • Zhang, Ying
  • Hou, Wei
  • Li, Jie
  • Zhu, Guanghui
  • Zhang, Xiaoxiao
  • Xu, Bowen
  • Wu, Zhe
  • Wang, Heping
  • SpringerLink (Online service)

Ähnliche Objekte (12)

PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer

PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer

AIH Therapy: Beyond First-Line

AIH Therapy: Beyond First-Line

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer

Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer

Rechallenge with First-Line Platinum Chemotherapy for Sensitive-Relapsed Small-Cell Lung Cancer

Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer

Mutational Profile Evaluates Response and Survival to First‐Line Chemotherapy in Lung Cancer

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer

Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer

Tongue as a first-line immune organ?

Tongue as a first-line immune organ?

Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib

Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590

Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study

Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study

First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis

First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis

Humoral First-Line Mucosal Innate Defence in vivo

Humoral First-Line Mucosal Innate Defence in vivo

Verbundene Objekte